Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone ± rituximab chemotherapy: results from an observational study.

Abstract

CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) ± rituximab [(± R)CHOP] is the current standard of care for aggressive non-Hodgkin lymphoma (NHL). Anemia resulting from chemotherapy can be treated with erythropoiesis-stimulating agents (ESAs). As part of the observational IMPACT NHL study, data were collected on ESA use and anemia-related outcomes in 1829 adults receiving (± R)CHOP-14 or (± R)CHOP-21. Overall, 33% of patients were anemic during chemotherapy. Older age, lower baseline hemoglobin (Hb), worse performance status, more advanced disease stage, and use of CHOP-14 were significant predictors of transfusion and anemia in logistic regression models. ESAs were received by 404 patients, usually in response to low or declining Hb levels. Most patients (65%) had Hb 9-11 g/dL at ESA initiation, and 89% (Kaplan-Meier percentage) achieved Hb 10-12 g/dL. In conclusion, two-thirds of anemic patients with NHL receiving (± R)CHOP initiated ESA treatment at Hb 9-11 g/dL, and most achieved target Hb levels (10-12 g/dL).

• Authors: Corinne Haioun, Antonio Salar, Ruth Pettengell, Hans Erik Johnsen, Ulrich Duehrsen, Francesca Gaia Rossi, Gregor Verhoef, Matthias Schwenkglenks, Ulrich Jaeger, Lisa Hamilton, Beatriz Pujol, Pieternella Johanna Lugtenburg
• Journal: Leukemia & lymphoma (Leuk Lymphoma) Vol. 52 Issue 5 Pg. 796-803 (May 2011) ISSN: 1029-2403 [Electronic] United States
• PMID: 21338278 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal, Murine-Derived
• Hematinics
• Hemoglobins
• Rituximab
• Vincristine
• Doxorubicin
• Cyclophosphamide
• Prednisolone

Topics

• Aged
• Anemia (chemically induced, drug therapy, etiology)
• Antibodies, Monoclonal, Murine-Derived (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Cyclophosphamide (administration & dosage)
• Doxorubicin (administration & dosage)
• Female
• Hematinics (administration & dosage)
• Hemoglobins (analysis)
• Humans
• Lymphoma, Non-Hodgkin (complications, drug therapy)
• Male
• Middle Aged
• Observation
• Prednisolone (administration & dosage)
• Retrospective Studies
• Rituximab
• Treatment Outcome
• Vincristine (administration & dosage)